Currently, Mounjaro is approved only for the treatment of type 2 diabetes
The opioid antagonist naloxone appears to block some of DSIPs effects, so combining these would likely negate DSIPs benefits
While DTC models may improve access and shift employer prescription costs, theres no evidence that they will solve the obesity burden or reduce total healthcare costs long-term
This study adds to the body of literature supporting the beneficial effects of semaglutide in people with overweight and obesity without diabetes, which is so necessary as we continue to navigate the complex landscape of insurance coverage of these medications in people who do not have diabetes, Shiara Ortiz-Pujols, MD, MPH, an obesity medicine physician at Staten Island University Hospital, told Healthline
If you find blood in stools (tarry stools) or if you experience severe diarrhoea, consult your doctor
Departamento de Bioqumica y Biologa Molecular, Universidad Peruana Cayetano Heredia